http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2025, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 23 Dec 2025 08:02:43 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/Vaccinex+secures+%2460+million+to+fund+alzheimer%27s+drug+trial/25773341.html <p>Vaccinex Inc. (NASDAQ: VCNX) announced a $60 million revenue sharing agreement with Pepinemab Development Venture LP to fund an enlarged phase 2b clinical trial of pepinemab for Alzheimer's disease treatment.</p><p>Under the agreement, PDV will receive 50% of future economic proceeds from neurological indication partnerships and 25% from other indications in exchange for funding. PDV is an investment entity established by FCMI, an existing Vaccinex investor whose chairman Albert Friedberg also chairs Vaccinex's board.</p><p>Pepinemab is an anti-SEMA4D antibody designed to inhibit semaphorin 4D induced pathology in the brain. Previous studies in animal models and the SIGNAL-AD phase 1/2a clinical trial showed http://www.streetinsider.com/Corporate+News/Vaccinex+secures+%2460+million+to+fund+alzheimer%27s+drug+trial/25773341.html Tue, 23 Dec 2025 08:02:43 -0500 VCNX http://www.streetinsider.com/Press+Releases/Vaccinex%2C+Inc.+Announces+%2460+million+Agreement+to+Finance+a%C2%A0Phase+2b+clinical+trial+of+pepinemab+to+treat+Alzheimer%E2%80%99s+Disease/25773307.html <p>ROCHESTER, N.Y., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating Alzheimer’s disease (AD) by inhibiting semaphorin 4D (SEMA4D) induced pathology in brain, today announced that it has entered into a $60 million revenue sharing agreement with Pepinemab Development Venture, LP (PDV) to continue advancing development of its pepinemab anti-SEMA4D antibody in an enlarged phase 2b clinical trial for treatment of AD. PDV LP is an investment entity established by FCMI, an existing Vaccinex investor. Albert Friedberg is Chairman of FCMI and of the Vaccinex Board. The agreements http://www.streetinsider.com/Press+Releases/Vaccinex%2C+Inc.+Announces+%2460+million+Agreement+to+Finance+a%C2%A0Phase+2b+clinical+trial+of+pepinemab+to+treat+Alzheimer%E2%80%99s+Disease/25773307.html Tue, 23 Dec 2025 08:01:00 -0500 A.14196687 O.00187565 O.21623884 VCNX VCNX http://www.streetinsider.com/Press+Releases/Vaccinex%2C+Inc.+Announces+%2460+million+Agreement+to+Finance+a%C2%A0Phase+2b+clinical+trial+of+pepinemab+to+treat+Alzheimer%E2%80%99s+Disease/25773307.html <p>ROCHESTER, N.Y., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating Alzheimer’s disease (AD) by inhibiting semaphorin 4D (SEMA4D) induced pathology in brain, today announced that it has entered into a $60 million revenue sharing agreement with Pepinemab Development Venture, LP (PDV) to continue advancing development of its pepinemab anti-SEMA4D antibody in an enlarged phase 2b clinical trial for treatment of AD. PDV LP is an investment entity established by FCMI, an existing Vaccinex investor. Albert Friedberg is Chairman of FCMI and of the Vaccinex Board. The agreements http://www.streetinsider.com/Press+Releases/Vaccinex%2C+Inc.+Announces+%2460+million+Agreement+to+Finance+a%C2%A0Phase+2b+clinical+trial+of+pepinemab+to+treat+Alzheimer%E2%80%99s+Disease/25773307.html Tue, 23 Dec 2025 08:01:00 -0500 A.14196687 O.00187565 O.21623884 VCNX VCNX http://www.streetinsider.com/Press+Releases/Vaccinex%2C+Inc.+Announces+%2460+million+Agreement+to+Finance+a%C2%A0Phase+2b+clinical+trial+of+pepinemab+to+treat+Alzheimer%E2%80%99s+Disease/25773307.html <p>ROCHESTER, N.Y., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating Alzheimer’s disease (AD) by inhibiting semaphorin 4D (SEMA4D) induced pathology in brain, today announced that it has entered into a $60 million revenue sharing agreement with Pepinemab Development Venture, LP (PDV) to continue advancing development of its pepinemab anti-SEMA4D antibody in an enlarged phase 2b clinical trial for treatment of AD. PDV LP is an investment entity established by FCMI, an existing Vaccinex investor. Albert Friedberg is Chairman of FCMI and of the Vaccinex Board. The agreements http://www.streetinsider.com/Press+Releases/Vaccinex%2C+Inc.+Announces+%2460+million+Agreement+to+Finance+a%C2%A0Phase+2b+clinical+trial+of+pepinemab+to+treat+Alzheimer%E2%80%99s+Disease/25773307.html Tue, 23 Dec 2025 08:01:00 -0500 A.14196687 O.00187565 O.21623884 VCNX VCNX http://www.streetinsider.com/Press+Releases/Vaccinex%2C+Inc.+Announces+%2460+million+Agreement+to+Finance+a%C2%A0Phase+2b+clinical+trial+of+pepinemab+to+treat+Alzheimer%E2%80%99s+Disease/25773307.html <p>ROCHESTER, N.Y., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating Alzheimer’s disease (AD) by inhibiting semaphorin 4D (SEMA4D) induced pathology in brain, today announced that it has entered into a $60 million revenue sharing agreement with Pepinemab Development Venture, LP (PDV) to continue advancing development of its pepinemab anti-SEMA4D antibody in an enlarged phase 2b clinical trial for treatment of AD. PDV LP is an investment entity established by FCMI, an existing Vaccinex investor. Albert Friedberg is Chairman of FCMI and of the Vaccinex Board. The agreements http://www.streetinsider.com/Press+Releases/Vaccinex%2C+Inc.+Announces+%2460+million+Agreement+to+Finance+a%C2%A0Phase+2b+clinical+trial+of+pepinemab+to+treat+Alzheimer%E2%80%99s+Disease/25773307.html Tue, 23 Dec 2025 08:01:00 -0500 A.14196687 O.00187565 O.21623884 VCNX VCNX http://www.streetinsider.com/Press+Releases/Vaccinex%2C+Inc.+Announces+%2460+million+Agreement+to+Finance+a%C2%A0Phase+2b+clinical+trial+of+pepinemab+to+treat+Alzheimer%E2%80%99s+Disease/25773307.html <p>ROCHESTER, N.Y., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating Alzheimer’s disease (AD) by inhibiting semaphorin 4D (SEMA4D) induced pathology in brain, today announced that it has entered into a $60 million revenue sharing agreement with Pepinemab Development Venture, LP (PDV) to continue advancing development of its pepinemab anti-SEMA4D antibody in an enlarged phase 2b clinical trial for treatment of AD. PDV LP is an investment entity established by FCMI, an existing Vaccinex investor. Albert Friedberg is Chairman of FCMI and of the Vaccinex Board. The agreements http://www.streetinsider.com/Press+Releases/Vaccinex%2C+Inc.+Announces+%2460+million+Agreement+to+Finance+a%C2%A0Phase+2b+clinical+trial+of+pepinemab+to+treat+Alzheimer%E2%80%99s+Disease/25773307.html Tue, 23 Dec 2025 08:01:00 -0500 A.14196687 O.00187565 O.21623884 VCNX VCNX http://www.streetinsider.com/Globe+Newswire/Vaccinex%2C+Inc.+Announces+%2460+million+Agreement+to+Finance+a%C2%A0Phase+2b+clinical+trial+of+pepinemab+to+treat+Alzheimer%E2%80%99s+Disease/25773307.html <p>ROCHESTER, N.Y., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating Alzheimer’s disease (AD) by inhibiting semaphorin 4D (SEMA4D) induced pathology in brain, today announced that it has entered into a $60 million revenue sharing agreement with Pepinemab Development Venture, LP (PDV) to continue advancing development of its pepinemab anti-SEMA4D antibody in an enlarged phase 2b clinical trial for treatment of AD. PDV LP is an investment entity established by FCMI, an existing Vaccinex investor. Albert Friedberg is Chairman of FCMI and of the Vaccinex Board. The agreements http://www.streetinsider.com/Globe+Newswire/Vaccinex%2C+Inc.+Announces+%2460+million+Agreement+to+Finance+a%C2%A0Phase+2b+clinical+trial+of+pepinemab+to+treat+Alzheimer%E2%80%99s+Disease/25773307.html Tue, 23 Dec 2025 08:01:00 -0500 A.14196687 O.00187565 O.21623884 VCNX VCNX http://www.streetinsider.com/Globe+Newswire/Vaccinex%2C+Inc.+Announces+%2460+million+Agreement+to+Finance+a%C2%A0Phase+2b+clinical+trial+of+pepinemab+to+treat+Alzheimer%E2%80%99s+Disease/25773307.html <p>ROCHESTER, N.Y., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating Alzheimer’s disease (AD) by inhibiting semaphorin 4D (SEMA4D) induced pathology in brain, today announced that it has entered into a $60 million revenue sharing agreement with Pepinemab Development Venture, LP (PDV) to continue advancing development of its pepinemab anti-SEMA4D antibody in an enlarged phase 2b clinical trial for treatment of AD. PDV LP is an investment entity established by FCMI, an existing Vaccinex investor. Albert Friedberg is Chairman of FCMI and of the Vaccinex Board. The agreements http://www.streetinsider.com/Globe+Newswire/Vaccinex%2C+Inc.+Announces+%2460+million+Agreement+to+Finance+a%C2%A0Phase+2b+clinical+trial+of+pepinemab+to+treat+Alzheimer%E2%80%99s+Disease/25773307.html Tue, 23 Dec 2025 08:01:00 -0500 A.14196687 O.00187565 O.21623884 VCNX VCNX http://www.streetinsider.com/Globe+Newswire/Vaccinex%2C+Inc.+Announces+%2460+million+Agreement+to+Finance+a%C2%A0Phase+2b+clinical+trial+of+pepinemab+to+treat+Alzheimer%E2%80%99s+Disease/25773307.html <p>ROCHESTER, N.Y., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating Alzheimer’s disease (AD) by inhibiting semaphorin 4D (SEMA4D) induced pathology in brain, today announced that it has entered into a $60 million revenue sharing agreement with Pepinemab Development Venture, LP (PDV) to continue advancing development of its pepinemab anti-SEMA4D antibody in an enlarged phase 2b clinical trial for treatment of AD. PDV LP is an investment entity established by FCMI, an existing Vaccinex investor. Albert Friedberg is Chairman of FCMI and of the Vaccinex Board. The agreements http://www.streetinsider.com/Globe+Newswire/Vaccinex%2C+Inc.+Announces+%2460+million+Agreement+to+Finance+a%C2%A0Phase+2b+clinical+trial+of+pepinemab+to+treat+Alzheimer%E2%80%99s+Disease/25773307.html Tue, 23 Dec 2025 08:01:00 -0500 A.14196687 O.00187565 O.21623884 VCNX VCNX http://www.streetinsider.com/Globe+Newswire/Vaccinex%2C+Inc.+Announces+%2460+million+Agreement+to+Finance+a%C2%A0Phase+2b+clinical+trial+of+pepinemab+to+treat+Alzheimer%E2%80%99s+Disease/25773307.html <p>ROCHESTER, N.Y., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating Alzheimer’s disease (AD) by inhibiting semaphorin 4D (SEMA4D) induced pathology in brain, today announced that it has entered into a $60 million revenue sharing agreement with Pepinemab Development Venture, LP (PDV) to continue advancing development of its pepinemab anti-SEMA4D antibody in an enlarged phase 2b clinical trial for treatment of AD. PDV LP is an investment entity established by FCMI, an existing Vaccinex investor. Albert Friedberg is Chairman of FCMI and of the Vaccinex Board. The agreements http://www.streetinsider.com/Globe+Newswire/Vaccinex%2C+Inc.+Announces+%2460+million+Agreement+to+Finance+a%C2%A0Phase+2b+clinical+trial+of+pepinemab+to+treat+Alzheimer%E2%80%99s+Disease/25773307.html Tue, 23 Dec 2025 08:01:00 -0500 A.14196687 O.00187565 O.21623884 VCNX VCNX http://www.streetinsider.com/Globe+Newswire/Vaccinex%2C+Inc.+Announces+%2460+million+Agreement+to+Finance+a%C2%A0Phase+2b+clinical+trial+of+pepinemab+to+treat+Alzheimer%E2%80%99s+Disease/25773307.html <p>ROCHESTER, N.Y., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating Alzheimer’s disease (AD) by inhibiting semaphorin 4D (SEMA4D) induced pathology in brain, today announced that it has entered into a $60 million revenue sharing agreement with Pepinemab Development Venture, LP (PDV) to continue advancing development of its pepinemab anti-SEMA4D antibody in an enlarged phase 2b clinical trial for treatment of AD. PDV LP is an investment entity established by FCMI, an existing Vaccinex investor. Albert Friedberg is Chairman of FCMI and of the Vaccinex Board. The agreements http://www.streetinsider.com/Globe+Newswire/Vaccinex%2C+Inc.+Announces+%2460+million+Agreement+to+Finance+a%C2%A0Phase+2b+clinical+trial+of+pepinemab+to+treat+Alzheimer%E2%80%99s+Disease/25773307.html Tue, 23 Dec 2025 08:01:00 -0500 A.14196687 O.00187565 O.21623884 VCNX VCNX http://www.streetinsider.com/Corporate+News/Vaccinex+%28VCNX%29+to+present+pepinemab+data+at+ASCO+2025/24850749.html <p>Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and Alzheimer’s disease (AD) through the inhibition of Semaphorin 4D (SEMA4D), today announced that it will <strong>present new data characterizing the unique mechanism of pepinemab to enhance immune responses to checkpoint therapies in the neoadjuvant setting that are associated with improved pathologic response in patients with head and neck cancer</strong>. Lead investigator and collaborator, Conor Steuer, MD from Winship Cancer Center at Emory University, will present results <strong>at the 2025 Annual Meeting of Clinical Oncology (ASCO) in Chicago on June 1, 2025</strong>.</p><p align="center"><strong>ASCO Conference Information:</strong></p><table http://www.streetinsider.com/Corporate+News/Vaccinex+%28VCNX%29+to+present+pepinemab+data+at+ASCO+2025/24850749.html Tue, 27 May 2025 08:46:05 -0500 VCNX http://www.streetinsider.com/Press+Releases/Vaccinex+to+Report+Promising+New+Clinical+Results+of+Neoadjuvant+Treatment+with+Pepinemab+to+Enhance+Immunotherapy+in+Patients+with+Head+and+Neck+Cancer+at+ASCO+Annual+Meeting/24850740.html <p><strong>Neoadjuvant treatment with pepinemab appears to induce abundant, mature lymphoid structures that correlate with improved pathologic response.</strong></p><p align="justify">ROCHESTER, N.Y., May 27, 2025 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and Alzheimer’s disease (AD) through the inhibition of Semaphorin 4D (SEMA4D), today announced that it will <strong>present new data characterizing the unique mechanism of pepinemab to enhance immune responses to checkpoint therapies in the neoadjuvant setting that are associated with improved pathologic response in patients with head and neck cancer</strong>. Lead investigator and collaborator, Conor Steuer, MD from http://www.streetinsider.com/Press+Releases/Vaccinex+to+Report+Promising+New+Clinical+Results+of+Neoadjuvant+Treatment+with+Pepinemab+to+Enhance+Immunotherapy+in+Patients+with+Head+and+Neck+Cancer+at+ASCO+Annual+Meeting/24850740.html Tue, 27 May 2025 08:45:00 -0500 VCNX http://www.streetinsider.com/Globe+Newswire/Vaccinex+to+Report+Promising+New+Clinical+Results+of+Neoadjuvant+Treatment+with+Pepinemab+to+Enhance+Immunotherapy+in+Patients+with+Head+and+Neck+Cancer+at+ASCO+Annual+Meeting/24850740.html <p><strong>Neoadjuvant treatment with pepinemab appears to induce abundant, mature lymphoid structures that correlate with improved pathologic response.</strong></p><p align="justify">ROCHESTER, N.Y., May 27, 2025 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and Alzheimer’s disease (AD) through the inhibition of Semaphorin 4D (SEMA4D), today announced that it will <strong>present new data characterizing the unique mechanism of pepinemab to enhance immune responses to checkpoint therapies in the neoadjuvant setting that are associated with improved pathologic response in patients with head and neck cancer</strong>. Lead investigator and collaborator, Conor Steuer, MD from http://www.streetinsider.com/Globe+Newswire/Vaccinex+to+Report+Promising+New+Clinical+Results+of+Neoadjuvant+Treatment+with+Pepinemab+to+Enhance+Immunotherapy+in+Patients+with+Head+and+Neck+Cancer+at+ASCO+Annual+Meeting/24850740.html Tue, 27 May 2025 08:45:00 -0500 VCNX http://www.streetinsider.com/Corporate+News/Vaccinex+%28VCNX%29+to+Report+Promising+New+Clinical+Data+Revealing+Pepinemab%E2%80%99s+Unique+Mechanism+to+Enhance+Immunotherapy/24659990.html <p>Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and Alzheimer’s disease (AD) through the inhibition of Semaphorin 4D (SEMA4D), today announced that it will present exciting new data characterizing the unique mechanism of pepinemab to enhance immune responses to checkpoint therapies, corresponding with improved survival benefit in patients with melanoma and head and neck cancer at the 2025 Annual Meeting of American Association for Cancer Research (AACR) in Chicago on April 29, 2025. Elizabeth Evans, PhD, Senior VP Discovery and Translational Medicine, will present results of these studies in two presentations<em>.</em></p><p> </p><table style="border-collapse: http://www.streetinsider.com/Corporate+News/Vaccinex+%28VCNX%29+to+Report+Promising+New+Clinical+Data+Revealing+Pepinemab%E2%80%99s+Unique+Mechanism+to+Enhance+Immunotherapy/24659990.html Mon, 21 Apr 2025 08:45:32 -0500 VCNX http://www.streetinsider.com/FDA/Vaccinex+%28VCNX%29+to+Report+Promising+New+Clinical+Data+Revealing+Pepinemab%E2%80%99s+Unique+Mechanism+to+Enhance+Immunotherapy/24659990.html <p>Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and Alzheimer’s disease (AD) through the inhibition of Semaphorin 4D (SEMA4D), today announced that it will present exciting new data characterizing the unique mechanism of pepinemab to enhance immune responses to checkpoint therapies, corresponding with improved survival benefit in patients with melanoma and head and neck cancer at the 2025 Annual Meeting of American Association for Cancer Research (AACR) in Chicago on April 29, 2025. Elizabeth Evans, PhD, Senior VP Discovery and Translational Medicine, will present results of these studies in two presentations<em>.</em></p><p> </p><table style="border-collapse: http://www.streetinsider.com/FDA/Vaccinex+%28VCNX%29+to+Report+Promising+New+Clinical+Data+Revealing+Pepinemab%E2%80%99s+Unique+Mechanism+to+Enhance+Immunotherapy/24659990.html Mon, 21 Apr 2025 08:45:32 -0500 VCNX http://www.streetinsider.com/Press+Releases/Vaccinex+to+Report+Promising+New+Clinical+Data+Revealing+Pepinemab%E2%80%99s+Unique+Mechanism+to+Enhance+Immunotherapy+at+Annual+Meeting+of+American+Association+for+Cancer+Research+%28AACR%29/24659986.html <p align="center"><em>Neoadjuvant treatment with pepinemab appears to induce abundant, mature lymphoid structures that correlate with durable clinical benefit of immunotherapy in patients with metastatic melanoma.</em></p> <p align="center"><em>Pepinemab, Semaphorin 4D blocking immunotherapy, also appears to induce the formation of efficient lymphoid structures in “cold” tumors of patients with recurrent and metastatic head and neck cancer.</em></p> <p align="justify">ROCHESTER, N.Y., April 21, 2025 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and Alzheimer’s disease (AD) through the inhibition of Semaphorin 4D (SEMA4D), today announced that it will <strong>present exciting http://www.streetinsider.com/Press+Releases/Vaccinex+to+Report+Promising+New+Clinical+Data+Revealing+Pepinemab%E2%80%99s+Unique+Mechanism+to+Enhance+Immunotherapy+at+Annual+Meeting+of+American+Association+for+Cancer+Research+%28AACR%29/24659986.html Mon, 21 Apr 2025 08:45:00 -0500 VCNX http://www.streetinsider.com/Globe+Newswire/Vaccinex+to+Report+Promising+New+Clinical+Data+Revealing+Pepinemab%E2%80%99s+Unique+Mechanism+to+Enhance+Immunotherapy+at+Annual+Meeting+of+American+Association+for+Cancer+Research+%28AACR%29/24659986.html <p align="center"><em>Neoadjuvant treatment with pepinemab appears to induce abundant, mature lymphoid structures that correlate with durable clinical benefit of immunotherapy in patients with metastatic melanoma.</em></p> <p align="center"><em>Pepinemab, Semaphorin 4D blocking immunotherapy, also appears to induce the formation of efficient lymphoid structures in “cold” tumors of patients with recurrent and metastatic head and neck cancer.</em></p> <p align="justify">ROCHESTER, N.Y., April 21, 2025 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and Alzheimer’s disease (AD) through the inhibition of Semaphorin 4D (SEMA4D), today announced that it will <strong>present exciting http://www.streetinsider.com/Globe+Newswire/Vaccinex+to+Report+Promising+New+Clinical+Data+Revealing+Pepinemab%E2%80%99s+Unique+Mechanism+to+Enhance+Immunotherapy+at+Annual+Meeting+of+American+Association+for+Cancer+Research+%28AACR%29/24659986.html Mon, 21 Apr 2025 08:45:00 -0500 VCNX http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++VACCINEX%2C+INC.++++++++++++For%3A+Dec+31/24643500.html si-local-file:///var/storage/secattach/20250415/24643500.html http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++VACCINEX%2C+INC.++++++++++++For%3A+Dec+31/24643500.html Tue, 15 Apr 2025 17:13:00 -0500 O.00187565 VCNX http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++VACCINEX%2C+INC.++++++++++++For%3A+Dec+31/24643500.html si-local-file:///var/storage/secattach/20250415/24643500.html http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++VACCINEX%2C+INC.++++++++++++For%3A+Dec+31/24643500.html Tue, 15 Apr 2025 17:13:00 -0500 O.00187565 VCNX http://www.streetinsider.com/SEC+Filings/Form++NT+10-K++++VACCINEX%2C+INC.++++++++++++For%3A+Mar+31/24578973.html si-local-file:///var/storage/secattach/20250401/24578973.html http://www.streetinsider.com/SEC+Filings/Form++NT+10-K++++VACCINEX%2C+INC.++++++++++++For%3A+Mar+31/24578973.html Tue, 01 Apr 2025 07:01:00 -0500 O.00187565 VCNX http://www.streetinsider.com/SEC+Filings/Form++NT+10-K++++VACCINEX%2C+INC.++++++++++++For%3A+Mar+31/24578973.html si-local-file:///var/storage/secattach/20250401/24578973.html http://www.streetinsider.com/SEC+Filings/Form++NT+10-K++++VACCINEX%2C+INC.++++++++++++For%3A+Mar+31/24578973.html Tue, 01 Apr 2025 07:01:00 -0500 O.00187565 VCNX http://www.streetinsider.com/SEC+Filings/Form++15-12G+++++VACCINEX%2C+INC.+++++++++++++++++++++++/24555820.html si-local-file:///var/storage/secattach/20250327/24555820.html http://www.streetinsider.com/SEC+Filings/Form++15-12G+++++VACCINEX%2C+INC.+++++++++++++++++++++++/24555820.html Thu, 27 Mar 2025 08:25:00 -0500 O.00187565 VCNX http://www.streetinsider.com/SEC+Filings/Form++15-12G+++++VACCINEX%2C+INC.+++++++++++++++++++++++/24555820.html si-local-file:///var/storage/secattach/20250327/24555820.html http://www.streetinsider.com/SEC+Filings/Form++15-12G+++++VACCINEX%2C+INC.+++++++++++++++++++++++/24555820.html Thu, 27 Mar 2025 08:25:00 -0500 O.00187565 VCNX http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++VACCINEX%2C+INC.+++++++++++++++++++++++/24548366.html si-local-file:///var/storage/secattach/20250326/24548366.html http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++VACCINEX%2C+INC.+++++++++++++++++++++++/24548366.html Wed, 26 Mar 2025 06:02:00 -0500 O.00187565 VCNX